Fujian South Pharmaceutical Co.,Ltd.

Established in 2001 in Mingxi County, Fujian Province, China, Fujian South Pharmaceutical (FSP) has become an important cGMP manufacturer of oncology APIs in China, cultivating 7,000 acres of Taxus wallichiana, the largest commercial cultivation of its kind in the country. FSP is a leading global supplier of natural and semi-synthesis paclitaxel, docetaxel and 10-DAB III, as well as gemcitabine, irinotecan, and patented technologies for docetaxel, imatinib and erlotinib, supported by a strong R&D team at its Shanghai center holding 6 PCT patents and 33 China patents for taxane, tabine and tinib processing.